For the first time, a Russian pharmaceutical company received a license for an analogue of a drug from the USA
For the first time, a Russian pharmaceutical company received a “compulsory license” to sell its analogue of a Western drug - a decision on this was made by the Moscow Arbitration Court, RBC reports. In 2016, the Russian company Nativa registered the drug Lenalidomide-Nativ, an antitumor immunomodulator for people with leprosy, tuberculosis, AIDS and multiple myeloma.